Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is developing various biologics product candidates, including Burosumab, a human monoclonal antibody that is in Phase III study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. It is also developing a range of small-molecule product candidates, such as UX007, a substrate replacement therapy that completed Phase II study for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome. In addition, the company is developing adeno-associated virus 8 (AAV8) gene therapy products comprising DTX301, an AAV8 for the treatment of OTC deficiency; DTX401, an AAV8 gene therapy program for the treatment of patients with GSDIa; and DTX201, a FVIII gene therapy program for the treatment of hemophilia A. It has a collaboration agreement with Rentschler Fill Solutions GmbH. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RARE
CUSIPN/A
Phone415-483-8800
Debt
Debt-to-Equity RatioN/A
Current Ratio9.16
Quick Ratio9.11
Price-To-Earnings
Trailing P/E Ratio-10.41
Forward P/E Ratio-16.94
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.61 million
Price / Sales1,501.55
Cash FlowN/A
Price / CashN/A
Book Value$8.68 per share
Price / Book9.00
Profitability
EPS (Most Recent Fiscal Year)($7.50)
Net Income$-302,130,000.00
Net Margins-703.27%
Return on Equity-44.09%
Return on Assets-37.65%
Miscellaneous
Employees520
Outstanding Shares50,180,000
Market Cap$3.82 billion
Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions
What is Ultragenyx Pharmaceutical's stock symbol?
Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."
How were Ultragenyx Pharmaceutical's earnings last quarter?
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) posted its quarterly earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($1.06) EPS for the quarter, beating the consensus estimate of ($2.08) by $1.02. The biopharmaceutical company earned $12.79 million during the quarter, compared to analysts' expectations of $5.63 million. Ultragenyx Pharmaceutical had a negative return on equity of 44.09% and a negative net margin of 703.27%. During the same quarter in the prior year, the firm posted ($1.72) EPS. View Ultragenyx Pharmaceutical's Earnings History.
When is Ultragenyx Pharmaceutical's next earnings date?
What price target have analysts set for RARE?
19 brokers have issued 1 year price objectives for Ultragenyx Pharmaceutical's stock. Their predictions range from $55.00 to $95.00. On average, they expect Ultragenyx Pharmaceutical's share price to reach $77.25 in the next twelve months. This suggests that the stock has a possible downside of 1.1%. View Analyst Price Targets for Ultragenyx Pharmaceutical.
What is the consensus analysts' recommendation for Ultragenyx Pharmaceutical?
19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 4 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ultragenyx Pharmaceutical.
What are Wall Street analysts saying about Ultragenyx Pharmaceutical stock?
Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock:
- 1. According to Zacks Investment Research, "Ultragenyx launched its second drug, Crysvita, in the United States to treat X-linked hypophosphatemia (XLH) in April. We are optimistic about the launch of Crysvita. In the EU, the drug was approved on a conditional basis, in February. The positive phase III data from the drug in pediatric setting, announced in May, should support the drug’s full approval in Europe. Meanwhile, a potential early FDA approval for UX007 for long-chain fatty acid oxidation disorders (LC-FAOD) could be a significant catalyst for the stock. The company also remains focused on its two-gene therapy programs, DTX301 for ornithine transcarbamylase (OTC) deficiency and DTX401 for glycogen storage disease type Ia/GSDIa. However, since Ultragenyx is a newly commercial company with small revenues, development or regulatory setbacks could result in higher operating expenses and the need for additional capital. Loss estimates have narrowed ahead of the Q2 earnings. " (7/24/2018)
- 2. JPMorgan Chase & Co. analysts commented, "RARE’s 3Q report this afternoon was relatively uneventful aside from a few small updates: 1) RARE now has biopsy data from 6 adult patients that are included in the FDA review of burosumab (KRN23); 2) 48 week Phase 3 data for burosumab in adults will be available by YE17; and 3) the DMTX acquisition could close as early as Nov 7 th . Additionally, the company plans on hosting an analyst day in NY on December 4 th during which they plan on sharing some additional details regarding their earlier stage pipeline." (11/5/2017)
Who are some of Ultragenyx Pharmaceutical's key competitors?
Some companies that are related to Ultragenyx Pharmaceutical include GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO), Beigene (BGNE), Sarepta Therapeutics (SRPT), Valeant Pharmaceuticals (VRX), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Alkermes (ALKS) and Ionis Pharmaceuticals (IONS).
Who are Ultragenyx Pharmaceutical's key executives?
Ultragenyx Pharmaceutical's management team includes the folowing people:
- Dr. Emil D. Kakkis, Pres, CEO & Director (Age 58)
- Ms. Shalini Sharp, CFO & Exec. VP (Age 43)
- Mr. Thomas R. Kassberg, Chief Bus. Officer & Exec. VP (Age 58)
- Mr. John Richard Pinion II, Chief Quality Officer & Exec. VP of Translational Sciences (Age 52)
- Mr. Theodore A. Huizenga, VP, Corp. Controller & Principal Accounting Officer (Age 47)
Has Ultragenyx Pharmaceutical been receiving favorable news coverage?
Press coverage about RARE stock has trended somewhat positive on Sunday, Accern Sentiment reports. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Ultragenyx Pharmaceutical earned a media and rumor sentiment score of 0.12 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 47.65 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for Ultragenyx Pharmaceutical.
Who are Ultragenyx Pharmaceutical's major shareholders?
Ultragenyx Pharmaceutical's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.75%), FMR LLC (6.89%), Federated Investors Inc. PA (2.82%), First Trust Advisors LP (1.96%), Voya Investment Management LLC (0.85%) and Brown Advisory Inc. (0.80%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View Institutional Ownership Trends for Ultragenyx Pharmaceutical.
Which major investors are selling Ultragenyx Pharmaceutical stock?
RARE stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Fred Alger Management Inc., Kornitzer Capital Management Inc. KS, Point72 Asset Management L.P., C WorldWide Group Holding A S, BNP Paribas Arbitrage SA, Highland Capital Management LP and GSA Capital Partners LLP. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View Insider Buying and Selling for Ultragenyx Pharmaceutical.
Which major investors are buying Ultragenyx Pharmaceutical stock?
RARE stock was bought by a variety of institutional investors in the last quarter, including Voya Investment Management LLC, Federated Investors Inc. PA, BlackRock Inc., Sector Gamma AS, Orbimed Advisors LLC, Bank of America Corp DE, Schwab Charles Investment Management Inc. and Cowen Inc.. View Insider Buying and Selling for Ultragenyx Pharmaceutical.
How do I buy shares of Ultragenyx Pharmaceutical?
Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ultragenyx Pharmaceutical's stock price today?
One share of RARE stock can currently be purchased for approximately $78.10.
How big of a company is Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical has a market capitalization of $3.82 billion and generates $2.61 million in revenue each year. The biopharmaceutical company earns $-302,130,000.00 in net income (profit) each year or ($7.50) on an earnings per share basis. Ultragenyx Pharmaceutical employs 520 workers across the globe.
How can I contact Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]
MarketBeat Community Rating for Ultragenyx Pharmaceutical (NASDAQ RARE)
MarketBeat's community ratings are surveys of what our community members think about Ultragenyx Pharmaceutical and other stocks. Vote "Outperform" if you believe RARE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARE will underperform the S&P 500 over the long term. You may vote once every thirty days.
